Efficacy of the Rezūm System for lower urinary tract symptoms in patients with benign prostatic hyperplasia: Long term results from a single centre prospective study

Abstract

Introduction:

Benign prostatic hyperplasia (BPH) is a prevalent urological condition leading to lower urinary tract symptoms. Minimal invasive surgical treatment (MISTs) such as Rezūm System are emerging aiming to relieve symptoms. We present results from a single centre prospective study.

Methods:

We prospectively followed patients undergoing Rezūm between 2021 and 2023 from a single centre. International Prostate Symptom Score (IPSS), functional outcomes (maximum urinary flow rate (Qmax) and post-void urinary residual (PVR) and International Index of Erectile Function-5 (IIEF-5) were assessed at 3, 6, 12 and 24 months. Anterograde ejaculation was assessed at 12 months follow up. Linear mixed-effects models (LMMs) for repeated measures were applied to assess differences in the IPSS, maximum flow rate (Qmax), PVR, and International Index of Erectile Function-5 (IIEF-5) from baseline (t0) to 3, 6, 12 and 24 months. Results: After adjusting for prostate volume and symptoms severity, significant differences were observed at 3, 6, 12 and 24 months for IPSS (p < 0.001), Qmax (p < 0.001), PVR (p < 0.001) and IPSS-QoL (p < 0.001) from baseline. No statistically significant changes were found in the IIEF-5 scores at 3, 6, 12 and 24 months from baseline. Anterograde ejaculation remained in 98% of patients after treatment.

Conclusions:

In conclusion, the study’s findings indicate that patients undergoing Rezūm treatment experience sustained improvements in IPSS, Qmax, PVR and IPSS-related quality of life up to 24 months following the intervention. Anterograde ejaculation remained in 98% of patients after treatment.

Keywords

Rezum BPH LUTS urology bladder outlet obstruction

Get full access to this article

View all access options for this article.

References

Madersbacher

Sampson

Culig

. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology 2019; 65(5): 458–464.

Miernik

Gratzke

. Current treatment for benign prostatic hyperplasia. Dtsch Ärztebl Int 2020; 117(49): 843–854.

Oelke

Bachmann

Descazeaud

, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013; 64(1): 118–140.

Roehrborn

Gange

Gittelman

, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 2017; 197(6): 1507–1516.

Foster

Barry

Dahm

, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol 2018; 200(3): 612–619.

Ghoz

Kesler

Hoogenboom

, et al. Decreasing colectomy rates in ulcerative colitis in the past decade: improved disease control? J Gastrointest Surg 2020; 24(2): 270–277.

Das

Han

Uhr

, et al. Benign prostatic hyperplasia: an update on minimally invasive therapy including Aquablation. Can J Urol 2020; 27(S3): 2–10.

Darson

Alexander

Schiffman

, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol 2017; 9: 159–168.

Dixon

Cedano

Mynderse

, et al. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm(®); system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 2015; 7: 13–18.

10.

McVary

Gange

Gittelman

, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016; 195(5): 1529–1538.

11.

Mollengarden

Goldberg

Wong

, et al. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer Prostatic Dis 2018; 21(3): 379–385.

12.

Coscarella

Al Barajraji

Moussa

, et al. Predicting the risk of failed trial without catheter following Rezum^TM therapy. World J Urol 2024; 42(1): 129.

13.

Haroon

Khan

McNicholas

, et al. Introduction of Rezum system technology to Ireland for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a pilot study on early outcomes and procedure cost analysis. Ir J Med Sci 2022; 191(1): 421–426.

14.

Bole

Gopalakrishna

Kuang

, et al. Comparative postoperative outcomes of Rezūm prostate ablation in patients with large versus small glands. J Endourol 2020; 34(7): 778–781.

15.

Garden

Shukla

Ravivarapu

, et al. Rezum therapy for patients with large prostates (⩾80 g): initial clinical experience and postoperative outcomes. World J Urol 2021; 39(8): 3041–3048.

16.

Siena

Cindolo

Ferrari

, et al. Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World J Urol 2021; 39(10): 3875–3880.

17.

Gratzke

Barber

Speakman

, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH 6 prospective, multicentre, randomized study. BJU Int 2017; 119(5): 767–775.

18.

Jones

Rajkumar

Rai

, et al. Medium-term outcomes of Urolift (minimum 12 months follow-up): evidence from a systematic review. Urology 2016; 97: 20–24.

19.

Gavi

Ragonese

Fettucciari

, et al. Efficacy of transurethral botulinum toxin A injections for bladder outlet obstruction: a systematic review and meta-analysis. Urologia 2024; 91(3): 468–476.

20.

Checcucci

Veccia

De Cillis

, et al. New ultra-minimally invasive surgical treatment for benign prostatic hyperplasia: a systematic review and analysis of comparative outcomes. Eur Urol Open Sci 2021; 33: 28–41.

21.

Cantiello

Fimognari

Di Mauro

, et al. Mechanical and ablative minimally invasive techniques for male LUTS due to benign prostatic obstruction: a systematic review according to BPH-6 evaluation. Urol Int 2021; 105(9–10): 858–868.

22.

Bientinesi

Coluzzi

Gavi

, et al. The impact of neurogenic lower urinary tract symptoms and erectile dysfunctions on marital relationship in men with multiple sclerosis: a single cohort study. J Clin Med 2022; 11(19): 5639.

23.

Donnell

. Minimally invasive therapy of lower urinary tract symptoms. Urol Clin North Am 2009; 36(4): 497–509.

24.

Bouza

López

Magro

, et al. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 2006; 6(1): 14.

25.

McVary

Gittelman

Goldberg

, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2021; 206(3): 715–724.